Abs.Pa

ABS.PA operates with a capital structure showing significant leverage, as total liabilities of €46.93 billion exceed total assets of €23.18 billion, resulting in negative equity of €23.75 billion. The company's liquidity position is constrained, with a current ratio of 0.71 and negative net cash after subtracting total debt. Free cash flow of -€7.32 billion indicates substantial cash outflows, while operating cash flow of €525 million provides limited near-term liquidity.

Profitability metrics reveal a challenging operating environment. The company reported a net loss of €7.83 billion and operating loss of €6.08 billion, with a return on assets of -33.8%. These results fall significantly below the industry median for pharmaceutical companies, which typically maintain positive operating margins and ROA above 10%. The gross profit of €1.25 billion suggests margin compression, likely driven by pricing pressures and R&D costs.

Geographically, ABS.PA's revenue is concentrated in North America and Europe, which together account for over 70% of total revenue. This concentration exposes the company to regulatory and pricing risks in developed markets, where reimbursement policies and patent expirations can significantly impact revenue streams.

The company's growth trajectory is mixed. While revenue of €10.72 billion shows modest year-over-year growth, the outlook for the current fiscal year indicates a contraction in earnings, with analysts forecasting a mean EPS of -€0.14 compared to -€0.15 in the previous period. The pharmaceutical industry is characterized by long development cycles and high R&D expenditures, which may delay near-term revenue growth.

Risk factors include liquidity constraints, with a debt-to-equity ratio of -0.78 and negative equity, which limits financial flexibility. The risk assessment indicates medium liquidity risk and low dilution potential, though the company's negative equity position could necessitate future capital raises. Recent filings highlight ongoing challenges in managing R&D costs and navigating patent expirations.

Recent events include a 10-K filing disclosing increased R&D expenses and a strategic shift toward oncology and rare diseases. Analysts have set a mean price target of €2.70, unchanged from the previous quarter, reflecting cautious expectations.